Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Phase 2
66
about 5.8 years
18+
1 site in NY
What this study is about
This trial is testing whether adding olanzapine to standard care helps manage anorexia (loss of appetite) in head and neck cancer patients receiving chemoradiation. Olanzapine is a medication being studied for its potential to reduce nausea and improve appetite in these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Best Practice
- 2.Questionnaire Administration
- 3.Take Olanzapine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
olanzapine
oral (Oral Tablet)
Primary: Average change in weight
Secondary: Change in Quality of Life, Change in quality of life (QOL) scores, Hospitalization rate, Incidence of adverse events
Oncology